Literature DB >> 10364505

Nucleotides 1506-1625 of bovine papillomavirus type 1 genome can enhance DNA packaging by L1/L2 capsids.

K N Zhao1, I H Frazer, W Jun Liu, M Williams, J Zhou.   

Abstract

We have previously described a DNA-packaging assay using bovine papillomavirus type 1 (BPV-1) virus-like particles (VLPs) and have identified a region of the BPV genome that assists in packaging. In this study, we identify a specific BPV sequence involved in DNA packaging by BPV-1 VLPs. In the initial screening of BPV-1 genomic sequences essential for DNA packaging, we observed that a plasmid with deletions between nucleotides (nt) 948 and 2113 failed to be packaged into BPV-1 VLPs. However, plasmids containing nt 948 to 2113 were efficiently packaged, suggesting that this 1.2-kb fragment contains a packaging enhancement sequence (PES). Further mapping of the BPV-1 genome showed that this packaging sequence lies between nt 1506 and 1625. Furthermore, this packaging sequence is also recognized by HPV6b VLPs, suggesting that a common packaging mechanism may be used by the two papillomavirus types. Given the phylogenetic difference between these two viral types, it is likely that other papillomavirus types may also use the same packaging mechanism. Identification of the PES has allowed a minimal viral genome sequence to be used in the packaging assay, improving the usefulness of the assay in studying the process of papillomavirus DNA encapsidation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364505     DOI: 10.1006/viro.1999.9714

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1.

Authors:  Kong-Nan Zhao; Ian H Frazer
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

Authors:  Latifa Bousarghin; Alba-Lucia Combita-Rojas; Antoine Touzé; Slimane El Mehdaoui; Pierre-Yves Sizaret; Maria-Mercedes Bravo; Pierre Coursaget
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Human papillomavirus type 18 chimeras containing the L2/L1 capsid genes from evolutionarily diverse papillomavirus types generate infectious virus.

Authors:  Brian S Bowser; Horng-Shen Chen; Michael J Conway; Neil D Christensen; Craig Meyers
Journal:  Virus Res       Date:  2011-07-06       Impact factor: 3.303

Review 4.  Papillomavirus assembly: An overview and perspectives.

Authors:  Carla Cerqueira; John T Schiller
Journal:  Virus Res       Date:  2016-11-10       Impact factor: 3.303

5.  Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16.

Authors:  S El Mehdaoui; A Touzé; S Laurent; P Y Sizaret; D Rasschaert; P Coursaget
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.

Authors:  M M Okun; P M Day; H L Greenstone; F P Booy; D R Lowy; J T Schiller; R B Roden
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Efficient intracellular assembly of papillomaviral vectors.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry.

Authors:  Patrick L Hindmarsh; Laimonis A Laimins
Journal:  Virol J       Date:  2007-02-26       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.